Literature DB >> 28660730

Fatty acid amide hydrolase (FAAH) inactivation confers enhanced sensitivity to nicotine-induced dopamine release in the mouse nucleus accumbens.

Francisco J Pavon1,2, Antonia Serrano1,2, Nimish Sidhpura2, Ilham Polis2, David Stouffer2, Fernando Rodriguez de Fonseca1, Benjamin F Cravatt3, Rémi Martin-Fardon2, Loren H Parsons2.   

Abstract

Nicotine exerts its rewarding effects by promoting an increase in dopamine (DA) release in the nucleus accumbens (NAc), and this process is influenced by the endocannabinoid system. Fatty acid amide hydrolase (FAAH) is the main enzyme responsible for the degradation of the endocannabinoid anandamide and other non-cannabinoid N-acylethanolamines. Previous research has reported that both genetic deletion and pharmacological inhibition of FAAH enhance nicotine-induced conditioned place preference at low doses. We conducted a microdialysis study to characterize nicotine-induced changes in DA and serotonin (5-HT) levels in the NAc of FAAH knockout (KO) mice using a conditioned place preference-like paradigm with three nicotine doses (0.1, 1 and 10 mg/kg, s.c.). Additionally, the effects of the selective FAAH inhibitor PF-3845 (10 mg/kg, i.p.) were also examined. Our data indicated that compared with wild-type mice, genetic deletion of FAAH selectively enhanced the effect of low-dose nicotine on DA release (p < 0.001) and resulted in a strong post-nicotine elevation in DA levels (p < 0.01). However, there were no differences between the genotypes at higher doses. Furthermore, FAAH KO mice displayed a moderate enhancement of the effect of low-dose nicotine on NAc 5-HT release (p < 0.05), with no differences between the genotypes at higher doses. Compared with vehicle-pretreated mice, mice pretreated with PF-3845 displayed an enhancement of the effect of low-dose nicotine on NAc DA release (p < 0.001), which resulted in a sustained increase in DA levels (p < 0.05). Similar to FAAH KO mice, PF-3845-pretreated mice displayed a moderate enhancement of the effect of low-dose nicotine on NAc 5-HT release (p < 0.01). These observations in mice suggest that enhanced nicotine-induced NAc DA release might contribute to increased sensitivity to the conditioned rewarding effects of low-dose nicotine following FAAH inhibition, which has been previously reported. Future studies combining behavioral and neurochemical approaches are needed to elucidate the precise mechanism of these effects.
© 2017 Society for the Study of Addiction.

Entities:  

Keywords:  FAAH; microdialysis; nicotine

Mesh:

Substances:

Year:  2017        PMID: 28660730      PMCID: PMC5747548          DOI: 10.1111/adb.12531

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  30 in total

Review 1.  The genetic basis of the endocannabinoid system and drug addiction in humans.

Authors:  Jose Antonio López-Moreno; Victor Echeverry-Alzate; Kora-Mareen Bühler
Journal:  J Psychopharmacol       Date:  2011-09-21       Impact factor: 4.153

2.  Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.

Authors:  Islam Gamaleddin; Carrie Wertheim; Andy Z X Zhu; Kathleen M Coen; Kiran Vemuri; Alex Makryannis; Steven R Goldberg; Bernard Le Foll
Journal:  Addict Biol       Date:  2011-04-26       Impact factor: 4.280

Review 3.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

4.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.

Authors:  B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

5.  Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence.

Authors:  A Castañé; E Valjent; C Ledent; M Parmentier; R Maldonado; O Valverde
Journal:  Neuropharmacology       Date:  2002-10       Impact factor: 5.250

6.  Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Neuroreport       Date:  2004-09-15       Impact factor: 1.837

Review 7.  Endocannabinoids and Their Pharmacological Actions.

Authors:  Roger G Pertwee
Journal:  Handb Exp Pharmacol       Date:  2015

8.  Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats.

Authors:  Maria Scherma; Leigh V Panlilio; Paola Fadda; Liana Fattore; Islam Gamaleddin; Bernard Le Foll; Zuzana Justinová; Eva Mikics; Jozsef Haller; Julie Medalie; Jessica Stroik; Chanel Barnes; Sevil Yasar; Gianluigi Tanda; Daniele Piomelli; Walter Fratta; Steven R Goldberg
Journal:  J Pharmacol Exp Ther       Date:  2008-08-25       Impact factor: 4.030

9.  Neuronal nicotinic acetylcholine receptors: neuroplastic changes underlying alcohol and nicotine addictions.

Authors:  Allison A Feduccia; Susmita Chatterjee; Selena E Bartlett
Journal:  Front Mol Neurosci       Date:  2012-08-03       Impact factor: 5.639

Review 10.  Endocannabinoids, related compounds and their metabolic routes.

Authors:  Filomena Fezza; Monica Bari; Rita Florio; Emanuela Talamonti; Monica Feole; Mauro Maccarrone
Journal:  Molecules       Date:  2014-10-24       Impact factor: 4.411

View more
  7 in total

1.  Inhibition of monoacylglycerol lipase reduces nicotine reward in the conditioned place preference test in male mice.

Authors:  Pretal P Muldoon; Lois S Akinola; Joel E Schlosburg; Aron H Lichtman; Laura J Sim-Selley; Anu Mahadevan; Benjamin F Cravatt; M Imad Damaj
Journal:  Neuropharmacology       Date:  2020-05-30       Impact factor: 5.250

2.  D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction.

Authors:  Esmaeil Mansouri; José N Nobrega; Matthew N Hill; Rachel F Tyndale; Francis S Lee; Christian S Hendershot; Laura M Best; Patricia Di Ciano; Georgia Balsevich; Mathew E Sloan; Stephen J Kish; Junchao Tong; Bernard Le Foll; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2019-11-27       Impact factor: 7.853

3.  Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography.

Authors:  Jussi Hirvonen; Paolo Zanotti-Fregonara; David A Gorelick; Chul Hyoung Lyoo; Denise Rallis-Frutos; Cheryl Morse; Sami S Zoghbi; Victor W Pike; Nora D Volkow; Marilyn A Huestis; Robert B Innis
Journal:  Biol Psychiatry       Date:  2018-07-21       Impact factor: 13.382

Review 4.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

5.  Selective inhibition of monoacylglycerol lipase is associated with passive coping behavior and attenuation of stress-induced dopamine release in the medial prefrontal cortex.

Authors:  Francisco Javier Pavón; Ilham Y Polis; David G Stouffer; Benjamin F Cravatt; Marisa Roberto; Rémi Martin-Fardon; Fernando Rodríguez de Fonseca; Loren H Parsons; Antonia Serrano
Journal:  Neurobiol Stress       Date:  2021-01-09

6.  Corticotropin-Releasing Factor Receptor-1 Neurons in the Lateral Amygdala Display Selective Sensitivity to Acute and Chronic Ethanol Exposure.

Authors:  Abigail E Agoglia; ManHua Zhu; Rose Ying; Harpreet Sidhu; Luis A Natividad; Sarah A Wolfe; Matthew W Buczynski; Candice Contet; Loren H Parsons; Marisa Roberto; Melissa A Herman
Journal:  eNeuro       Date:  2020-03-05

Review 7.  New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence.

Authors:  Rocio Saravia; Marc Ten-Blanco; Inmaculada Pereda-Pérez; Fernando Berrendero
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.